Pharma major Lupin Limited (Lupin) announced that it has received approval for its Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. Lupin is the first generic company to receive an approval for generic Inderal®-LA Capsules for the Canadian market and the product has been approved and will be manufactured from Lupin’s Pithampur Unit-2 Facility.
Lupin’s Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg, are the generic version of Inderal®-LA Capsules, 60 mg, 80 mg, 120 mg and 160 mg of Pfizer Canada ULC, and are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris.
Propranolol Hydrochloride Extended-Release (ER) Capsules (Canadian Reference Product: Inderal®-LA Capsules) had an annual sales of approximately CAD 8.6 million.
